Recent Finacing
Recent Raise
Asceneuron is a clinical-stage Lausanne biotech developing orally bioavailable small-molecule O-GlcNAcase inhibitors and M1 muscarinic PAMs to modulate tau pathology and cholinergic signaling for neurodegenerative diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
